Objectives: This study compared the visual outcomes and optical quality of two monofocal, aspheric intraocular lenses (IOLs; CT LUCIA 621P, Carl Zeiss Meditec; Eyhance ICB00, Johnson & Johnson Vision) by evaluating visual acuity, contrast sensitivity, and higher-order aberrations 1 month post-cataract surgery. Methods: In this retrospective, comparative study, 120 eyes (72 patients) that underwent cataract surgery with either CT LUCIA 621P (Lucia group) or Eyhance ICB00 (Eyhance group) implantation (60 eyes/group) were retrospectively investigated. Visual acuity at various distances and defocus curves were measured 1 month postoperatively. Optical quality was assessed by comparing contrast sensitivity and internal coma, spherical, and total aberrations by using iTrace (Tracey Technology), a ray-tracing-type aberrometer. Results: The visual acuity and defocus curves were similar between the two IOLs 1 month postoperatively. The Lucia group showed better contrast sensitivity at higher spatial frequencies: 12 cpd (p < 0.001, 1.32 LogCS vs. 1.02 LogCS) and 18 cpd (p = 0.009, 0.74 LogCS vs. 0.47 LogCS) unilaterally and 18 cpd (p = 0.044, 0.94 LogCS vs. 0.60 LogCS) bilaterally. Postoperative internal spherical aberration was significantly lower in the Lucia group (p < 0.001, −0.04 µm vs. −0.003 µm). Internal coma and total aberrations were similar. Conclusions: The visual acuity and defocus curves of the Lucia and Eyhance groups were comparable 1 month post-cataract surgery. The Lucia group’s superior contrast sensitivity and lower postoperative internal spherical aberration were due to differences in IOL designs, particularly the power variation patterns.

Objectives: To compare the long-term efficacy and safety of intense pulsed light (IPL) treatments using a 590-nm and an acne filter. Methods: In this prospective, randomized, paired-eye trial study, 30 patients with moderate and severe meibomian gland dysfunction (MGD) were followed up for at least one month after their last treatment. Group A received IPL treatment with an acne filter, a type of notch filter that blocks wavelengths between 600 and 800 nm, allowing IPL to emit wavelengths between 400–600 nm and 800–1200 nm. Group B received treatment with a 590 nm filter, a type of cut-off filter that blocks wavelengths below 590 nm. Clinical parameters, including tear osmolarity, matrix metalloproteinase (MMP)-9 expression, tear break-up time, ocular surface staining scores, Schirmer’s test I, lid margin telangiectasia scores, MG expressibility/secretion scores, and Ocular Surface Disease Index scores, were measured at baseline, 1, 6, and 12 months after their last treatment. Results: In the linear mixed model, significant time effects on all clinical parameters, except for MMP-9 grades and Schirmer’s test I results, were observed within each group. However, interactions between time points (baseline, 6 months, 12 months) and groups (Group A, B) were not significant. The generalized estimating equation model showed no significant interaction between time points and groups for MMP-9 positivity; however, a significant time effect on MMP-9 positivity was observed in Group A, with a decrease at 12 months after their last treatment when compared to baseline and 6 months. Conclusions: The IPL treatment modality for moderate to severe MGD demonstrated a significant therapeutic effect for one year under strictly controlled self-administration of other treatments. IPL treatment using acne filter is a promising treatment option for reducing MMP-9 positivity in MGD patients.

Objectives: To investigate the clinical characteristics of patients with meibomian gland dysfunction (MGD) who are refractory to additional intense pulsed light (IPL) treatment. Materials and Methods: This retrospective study included 66 eyes of 66 patients with moderate-to-severe MGD who had previously undergone four sessions of IPL treatment with a 590 nm filter at another clinic and, received an additional four sessions of IPL treatment with a vascular filter. Patients’ subjective assessments before and after the additional IPL treatments were scored on a scale from 0 to 4, where 0 = moderate improvement, 1 = mild improvement, 2 = no change, and 3 = aggravated MGD. Patients who scored 0 or 1 were classified as Group 1 (Responsive group), while those who scored 2 or 3 were classified as Group 2 (Refractory group). Results: Among the 66 eyes from 66 patients, Group 1 comprised 32 eyes and Group 2 comprised 34 eyes. Patients in the refractory group, who did not respond to additional IPL treatment, exhibited poor ocular staining scores before additional IPL treatment. The responsive group showed better treatment responses with regard to the Oxford and Sjögren’s International Clinical Collaborative Alliance (SICCA) staining scores (all p < 0.001), upper and lower lid meibum quality and meibum consistency, and meibomian gland grade (all p < 0.001). Changes in the Oxford staining score (p = 0.032), SICCA staining score (p = 0.003), meibum quality (p < 0.001), meibum consistency (p < 0.001), and meibomian gland grade (p < 0.001), before and after the additional treatment, were significantly greater in Group 1 than in Group 2. Conclusions: Additional IPL treatment with a vascular filter may provide further clinical benefits in selected patients with moderate-to-severe MGD who have previously undergone IPL therapy. Poor baseline ocular surface staining was associated with a lower likelihood of treatment response and may help identify patients who are less likely to benefit from additional IPL treatment.

Background/Objectives: Visual recovery after cataract surgery may be affected by lifestyle and environmental factors. This study aimed to investigate the association between daily outdoor activity and patient-reported visual outcomes after cataract surgery under perioperative management using cyclosporine and rebamipide. Methods: This retrospective study included 90 eyes from patients who underwent standardized cataract surgery with implantation of TECNIS Eyhance intraocular lenses. Patients were divided into two groups based on their average daily outdoor activity during the first postoperative month: Group 1 (≤3 h/day) and Group 2 (>3 h/day). Postoperative assessments included Cataract-related Visual Function Questionnaire (CVFQ) scores, uncorrected and corrected distance visual acuity, and ocular surface parameters such as tear breakup time, Oxford score, SICCA score, and OSDI. Results: Group 1 reported significantly higher CVFQ scores for daytime (p = 0.020) and night-time driving (p = 0.037) compared to Group 2, indicating lower levels of visual discomfort in these tasks. No significant differences were observed between the groups for other CVFQ subcategories or ocular surface parameters. Conclusions: Except for driving-related discomfort, no significant differences were found in CVFQ scores between the groups. No difference in ocular surface parameters can be attributed to the perioperative management using cyclosporine and rebamipide. CVFQ may be a useful tool for assessing subjective visual outcomes after cataract surgery.

Objectives: To investigate the effectiveness of scleral lenses following corneal cross-linking (CXL) in patients with progressive keratoconus. Methods: This retrospective study analyzed patients with keratoconus who underwent CXL and subsequently used scleral lenses for at least one year. A total of 21 patients (23 eyes) with progressive keratoconus were included. CXL was performed using the epithelium-off cross-linking technique following the Dresden protocol. Corneal astigmatism (CA), white-to-white distance, thinnest corneal thickness, and central corneal thickness (CCT) were assessed using corneal topography and tomography. Data were collected before CXL, at one month postoperatively, at the time of scleral lens prescription, and at 1, 3, 6, and 12 months after scleral lens use. Results: The mean age of the patients was 24.6 ± 4.6 years. The baseline uncorrected visual acuity (logMAR) before CXL was 1.05 ± 0.52. The baseline Kmax and CA were 53.01 ± 6.99 and −5.83 ± 3.23 D, respectively. The mean CCT was 444.09 ± 61.82 µm. The mean interval between CXL and scleral lens prescription was 6.75 ± 8.49 months. Following CXL, the Kmean decreased from 49.61 to 45.79 (p = 0.056), Kmax decreased from 53.01 to 51.32 (p = 0.053), and CA decreased from −5.83 to −4.91 D (p = 0.051), albeit statistically non-significant. At the 12-month follow-up after scleral lens prescription, Kmean and Kmax values remained stable, indicating no disease progression. Compared with baseline values before CXL, Kmean, Kmax, and CA were significantly reduced at the 12-month follow-up after scleral lens prescription (p = 0.047, p = 0.049, and p = 0.042, respectively). Scleral lens-corrected visual acuity was significantly better than habitual corrected visual acuity at all follow-up time points. Conclusions: Scleral lens application following CXL was associated with improved corrected visual acuity, and corneal keratometric values remained stable during lens wear.